key: cord-0873808-cwqsbwaj
authors: Antoine, Rebendenne; Valadão Ana Luiza, Chaves; Marine, Tauziet; Ghizlane, Maarifi; Boris, Bonaventure; Rémi, Planès; Joe, McKellar; Sébastien, Nisole; Mary, Arnaud-Arnould; Olivier, Moncorgé; Caroline, Goujon
title: SARS-CoV-2 replication triggers an MDA-5-dependent interferon production which is unable to efficiently control replication
date: 2020-10-28
journal: bioRxiv
DOI: 10.1101/2020.10.28.358945
sha: f670edaf6fad4bc602cd348d83f778107b028488
doc_id: 873808
cord_uid: cwqsbwaj

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third highly pathogenic coronavirus to spill over to humans in less than 20 years, after SARS-CoV-1 in 2002-2003 and Middle East respiratory syndrome (MERS)-CoV in 2012. SARS-CoV-2 is the etiologic agent of coronavirus disease 19 (COVID-19), which ranges from mild respiratory symptoms to severe lung injury and death in the most severe cases. The COVID-19 pandemic is currently a major health issue worldwide. Immune dysregulation characterized by altered innate cytokine responses is thought to contribute to the pathology of COVID-19 patients, which is a testimony of the fundamental role of the innate immune response against SARS-CoV-2. Here, we further characterized the host cell antiviral response against SARS-CoV-2 by using primary human airway epithelia and immortalized model cell lines. We mainly focused on the type I and III interferon (IFN) responses, which lead to the establishment of an antiviral state through the expression of IFN-stimulated genes (ISGs). Our results demonstrate that both primary airway epithelial cells and model cell lines elicit a robust immune response characterized by a strong induction of type I and III IFN through the detection of viral pathogen molecular patterns (PAMPs) by melanoma differentiation associated gene (MDA)-5. However, despite the high levels of type I and III IFNs produced in response to SARS-CoV-2 infection, the IFN response was unable to control viral replication, whereas IFN pre-treatment strongly inhibited viral replication and de novo production of infectious virions. Taken together, these results highlight the complex and ambiguous interplay between viral replication and the timing of IFN responses.

cells and model cell lines elicit a robust immune response characterized by a strong induction of type I and III IFN through the detection of viral pathogen molecular patterns (PAMPs) by melanoma differentiation associated gene (MDA)-5. However, despite the high levels of type I and III IFNs produced in response to SARS-CoV-2 infection, the IFN response was unable to control viral replication, whereas IFN pre-treatment strongly inhibited viral replication and de novo production of infectious virions. Taken together, these results highlight the complex and ambiguous interplay between viral replication and the timing of IFN responses.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current coronavirus disease 2019 pandemic. This virus emerged in China at the end of 2019 (Zhou et al., 2020a; Zhu et al., 2020) and has, since then, dramatically spread across the world. As of today (October 28th, 2020), SARS-CoV-2 has caused more than 1,172,000 deaths worldwide, general lockdowns in many countries across the world and an unprecedented global economic crisis, as well as an undeniable pressure on health systems. SARS-CoV-2 is closely related to the highly pathogenic SARS-CoV-1, which caused an outbreak in [2002] [2003] in South East China and Hong Kong, with a fatality rate close to ~10% (Drosten et al., 2003; Peiris et al., 2003; Zhong et al., 2003) . COVID-19 has many of the hallmarks of SARS-CoV disease including fever, breathing difficulty, acute respiratory distress syndrome (ARDS) and death in the most severe cases . SARS-CoV-2 is also related to Middle East Respiratory Syndrome coronavirus (MERS-CoV), another highly pathogenic coronavirus discovered in 2002, causing an ARDS and organ failure in the most severe cases, and death in ~35% of cases (Zaki et al., 2012) . The estimated fatality rate of SARS-CoV-2 infection is much lower, but still fairly high (estimated to be ~0.5-1%), and this virus has clearly shown a great potential for transmission between humans. Four additional coronaviruses, known to infect humans, circulate in the population every winter, mainly causing common colds: the human coronaviruses (HCoV)-229E, -OC43, -NL63, and -HKU1.

Together with SARS-CoV-1 and MERS-CoV, SARS-CoV-2 belongs to the genus betacoronavirus. They are enveloped viruses with large positive-sense RNA genomes of approximately 30 kilobases. The genome of SARS-CoV-2 shares 79.6% identity with SARS-CoV-1 and 50% with MERS-CoV (Zhou et al., 2020a) . SARS-CoV-2 mainly replicates in the respiratory tract, but can also replicate in the gastrointestinal tract (Xiao et al., 2020) . Similarly to SARS-CoV-1 and HCoV-NL63, SARS-CoV-2 entry into target cells is mediated by the Angiotensin converting enzyme 2 (ACE2) receptor Hofmann et al., 2005; Li et al., 2003; Zhou et al., 2020b) . Recently, Neuropilin-1 was identified as an important cofactor implicated in SARS-CoV-2 entry (Cantuti-Castelvetri et al., 2020) . The cellular serine protease Transmembrane protease, serine 2 (TMPRSS2) is employed by both SARS-CoV-1 and -2 for Spike (S) protein priming at the plasma membrane Matsuyama et al., 2010) . Cathepsins may also be involved in SARS-CoV S cleavage and fusion peptide exposure, upon entry via an endocytic route (Huang et al., 2006; Ou et al., 2020; Simmons et al., 2005) . (Park and Iwasaki, 2020) . Genetic studies have shown that mouse hepatitis virus (MHV), a murine coronavirus, is sensed by both RIG-I and MDA-5, with a critical role of the latter in vivo (Li et al., 2010; Park and Iwasaki, 2020; Sa Ribero et al., 2020; Zalinger et al., 2015) . TLR3 seems to play an important role in the sensing of MHV, SARS-CoV-1 and MERS-CoV in plasmacytoid dendritic cells (Cervantes-Barragan et al., 2007 , Scheuplein et al., 2015 .

However, the role of known PRRs in SARS-CoV-2 sensing has yet to be elucidated.

PRR activation leads to the production and secretion of type I and III interferons, proinflammatory cytokines, eicosanoids and chemokines, which can act in a paracrine and autocrine manner. In particular, type I and III IFNs constitute one of the first lines of defence against viral infections, through the regulation of hundreds of interferon-stimulated genes (ISGs), which induce an antiviral state in infected and neighbouring cells. Type I IFNs include 17 subtypes (13 IFN-α, IFN-β, IFN-ε, IFN-κ, IFN-ω) and type III IFNs include four subtypes: IFN-λ1 (IL-29), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B), and IFN-λ4 (Lazear et al., 2019) . Receptors for type I IFN (IFNAR1 and 2) are ubiquitously expressed, whereas IFN-III receptors are preferentially expressed on mucosal epithelial cells, as well as liver cells and some myeloid cells (Kotenko et al., 2019; Wack et al., 2015) . Both type I and III IFNs induce ISGs but type I IFN leads to a more rapid induction and decline of ISG expression and is more pro-inflammatory than type III (Lazear et al., 2019) .

Type I and III IFNs treatments have been shown to inhibit the replication of SARS-CoV-1 (Haagmans et al., 2004; Paragas et al., 2005; Zheng et al., 2004) , and more dramatically that of MERS-CoV (Chan et al., 2015; Hart et al., 2014; de Wilde et al., 2013) and SARS-CoV-2 (Blanco-Melo et al., 2020; Dinnon et al., 2020; Hassan et al., 2020; Israelow et al., 2020a; Lei et al., 2020a; Lokugamage et al., 2020; Stanifer et al., 2020) , both in vitro and in vivo. However, SARS-CoV-2 dampens type I and III IFN induction and subsequent expression of ISGs (Blanco-Melo et al., 2020; Israelow et al., 2020b; Lei et al., 2020a Lei et al., , 2020b . Upon SARS-CoV-1 infection of mice, a similar phenotype was observed and was associated with a delayed type I IFN signalling, which was linked to disease severity.

Indeed, type I IFN promoted accumulation of pathogenic monocyte-macrophages, resulting in lung immunopathology, vascular leakage, and suboptimal T cell responses, whereas early type I IFN administration or impairment of type I IFN signalling at later stages upon infection ameliorated immunopathology (Channappanavar et al., 2016) .

Consistent with this, the recruitment of proinflammatory cells was dependent on type I IFN signalling, but not the viral clearance in a murine model of infection by SARS-CoV-2 (Israelow et al., 2020a) , suggesting that IFNs might be more deleterious than beneficial in vivo. However, in COVID-19 patients, the levels of circulating IFN-b were undetectable and an impaired IFN-a production seemed to characterize the most severe cases (Arunachalam et al., 2020; Hadjadj et al., 2020) . Moreover, neutralizing auto-antibodies against type I IFNs were found in at least 10% of life-threatening COVID-19 patients . Furthermore, 3,5% of the critically ill patients with severe COVID-19 carried inborn errors in genes involved in the type I IFN pathway such as TLR3, IRF7 or IFNAR1 . Taken together, this highlights a critical role of IFNs in COVID-19 disease severity and the importance of better understanding the interplay between SARS-CoV-2 and the IFN system.

In this article, we aimed to characterize cell host responses to SARS-CoV-2 infection and the role of IFNs in the control of viral replication, using primary human airway epithelia and immortalized model cell lines. First, we showed that primary human airway epithelial cells supported high levels of SARS-CoV-2 replication and were capable of sensing this virus, with a potent induction of genes involved in innate immunity, including type I and III IFNs, and production of these cytokines in their basal media. However, this response arrived late upon viral exposure (after 48 h). The naturally permissive Calu-3 lung cell line recapitulated IFN induction upon SARS-CoV-2 exposure, which validated the use of this model cell line as a tool to study SARS-CoV-2 replication and induction of innate immunity.

ACE2-transduced, lung A549 and intestinal Caco-2 cell lines were also able to detect SARS-CoV-2 virus, albeit with different efficiencies. Interestingly, all these cell types could inhibit SARS-CoV-2 replication to different levels upon type I IFN pre-exposure. Using Calu-3 cells, we further showed that MDA-5 was the main innate immune sensor of SARS-CoV-2 in these epithelial cells. Finally, we demonstrated that type I and III IFN production elicited by SARS-CoV-2 infection was unable to inhibit replication, supporting the idea that the timing of IFN exposure is key to control replication.

SARS-CoV-2 BetaCoV_France_IDF0372_2020_C2 isolate (obtained from Pasteur Institute) was amplified and titrated on Vero E6 cells by plaque assays. In order to analyse host cell responses to SARS-CoV-2 infection in physiological targets, 3D Human Airway Epithelia (HAE; MucilAir™ cells, Epithelix) were mock-infected or incubated with SARS-CoV-2 on the apical side at a MOI of 0,01 or 0,1. Viral replication was analysed at the indicated time points, by monitoring the copy number of RNA polymerase RNA dependent (RdRp) RNAs in cells by . As shown previously (Pizzorno et al., 2020) , these primary cells were highly permissive to SARS-CoV-2 replication.

Immunofluorescence analyses confirmed detection of double-stranded RNA in SARS-CoV-2 infected HAE cells but not in non-infected cells ( Figure 1B ). The basal media was harvested at 72 h post-infection, and cytokine production was measured using the Human Anti-Virus Response Panel LEGENDplex™ ( Figure 1C ). A strong IFN response was observed, with a massive production of both type I (IFN-b) and type III (IFN-l1, and 2/3)

IFNs. An important induction of CXCL10 (also named IP-10) production was also observed, along with a more modest induction of pro-inflammatory cytokines IL-6, IL-8 and TNF-a. A RT-qPCR experiment on samples collected at 24, 48 and 72 h post-infection confirmed an important induction of IFNB1, IFNL1 and L2 at 48 h and 72 h after infection with SARS-CoV-2, which was not observed at 24 h, and parallel induction of prototype ISGs ( Figure S1B ). Next, a RT 2 profiler analysis using the Antiviral Response panel was performed at 72 h post infection ( Figure 1D ). As expected, IFNB and other genes belonging to the IFN system (e.g. STAT1, TICAM1, TLR3, TLR7, TLR8, DDX58, IRF7, as well as antiviral effector ISGs, such as OAS2 and MX1) were confirmed to be upregulated.

A potent induction of the inflammasome genes NLRP3 and MEFV (encoding Pyrin, also known as TRIM20) was interestingly also observed, as well as CXCL10, CXCL11, CCL3 and CCL5 chemokine induction. Of note, HAE cells from nasal, tracheal and bronchial origins behaved globally similarly with respect to their responses to infection ( Figure S1C and D). Concentration (pg/ml) CXCL9  CYLD  TKFC  DDX3X  DDX58  DHX58  FADD  FOS  HSP90AA1  IFIH1  IFNA1  IFNA2  IFNAR1  IFNB1  IKBKB  IL12A  IL12B  IL15  IL18  IL1B  IL6  CXCL8  IRAK1  IRF3  IRF5  IRF7  ISG15  JUN  MAP2K1  MAP2K3  MAP3K1  MAP3K7  MAPK1  MAPK14  MAPK3  MAPK8  MAVS  MEFV  MX1  MYD88  NFKB1  NFKBIA  NLRP3  NOD2  OAS2  PIN1  PSTPIP1  PYCARD  PYDC1  RELA  RIPK1  SPP1  STAT1  SUGT1  TBK1  TICAM1  TLR3  TLR7  TLR8  TLR9  TNF  TRADD  TRAF3  TRAF6  TRIM25 10 -1 analysis was performed using the RNAs extracted at 72 h (MOI 0,1). The mean of 4 (A) or 3 (C and D) independent experiments is shown, with error bars representing one standard deviation (s.d.) from the mean.

Next, a number of immortalized, epithelial human cell lines were tested for their ability to support viral replication, in comparison to simian Vero E6 cells ( Figure S2 ). Calu-3 (lung adenocarcinoma), Caco-2 (colorectal adenocarcinoma) (both known to express SARS-CoV-2 receptor ACE2 and TMPRSS2 protease and be permissive to SARS-CoV-2 were used in parallel to A549 (epithelial, lung carcinoma) genetically modified to express ACE2, together with TMPRSS2 or not. We also genetically modified Caco-2 cells to express higher levels of ACE2, or ACE2 and TMPRSS2 in combination. The cells were infected with SARS-CoV-2 and lysed 48 h later to measure viral replication using a RdRp RT-qPCR. Calu-3, Caco-2-ACE2 and A549-ACE2 supported SARS-CoV-2 replication to a very similar extent ( Figure S2 ) and were therefore selected for further studies.

Responses to infection were next evaluated in Calu-3 cells ( Figure 2 ). The cells were infected at the indicated MOIs and replication efficiency was assessed by measuring RdRp copy numbers ( Figure 2A ). Whereas replication efficiency increased concomitantly with the viral input at 24 h, a plateau was reached at 48 h. Cytokine production in Calu-3 supernatants was measured and a very similar response than that in HAE cells was observed, with a high induction of IFN-b, IFN-l1 and IFN-l2/3, CXCL10 and a slight induction of IL-6 and TNF-a ( Figure 2B ). RT 2 profiler and RT-qPCR analyses confirmed a globally similar response of Calu-3 cells to SARS-CoV-2 infection as compared to HAE cells ( Figure 2C and Figure S3A ), with a high induction of IFNB1, IFNL2 and a moderate induction of ISGs. However, these responses happened more rapidly than in HAE cells ( Figure S1B and S3A). Type I and III IFN production in supernatants from infected Calu-3 cells was confirmed using reporter cell lines ( Figure S3B and C). High and moderate induction levels of IFNB1, IFNL2, and prototype ISGs ISG15 and MX1 were observed in infected A549-ACE2 and Caco2-ACE2, respectively, upon SARS-CoV-2 replication ( Figure S4 ). Having established that SARS-CoV-2 infected cells produced high amounts of IFN, we sought to identify the PRR(s) responsible for sensing the virus. Typically, coronaviruses are sensed via RIG-I and/or MDA-5 PRRs (Li et al., 2010; Zalinger et al., 2015) , which then signal through mitochondrial antiviral-signalling protein (MAVS). We therefore used RdRp mRNA (copy number) HSP90AA1  IFIH1  IFNA1  IFNA2  IFNAR1  IFNB1  IKBKB  IL12A  IL12B  IL15  IL18  IL1B  IL6  CXCL8  IRAK1  IRF3  IRF5  IRF7  ISG15  JUN  MAP2K1  MAP2K3  MAP3K1  MAP3K7  MAPK1  MAPK14  MAPK3  MAPK8  MAVS  MEFV  MX1  MYD88  NFKB1  NFKBIA  NLRP3  NOD2  OAS2  PIN1  PSTPIP1  PYCARD  PYDC1  RELA  RIPK1  SPP1  STAT1  SUGT1  TBK1  TICAM1  TLR3  TLR7  TLR8  TLR9  TNF  TRADD  TRAF3  TRAF6  TRIM25 10 CRISPR/Cas9 to generate cell populations knockout for RIG-I, MDA-5 or MAVS and tested the ability of these cells to produce type I and III IFNs upon SARS-CoV-2 infection ( Figure 3 ). We observed that MDA-5 and MAVS depletion, but not RIG-I depletion,

drastically impacted the amounts of type I and type III IFNs produced, demonstrating that in Calu-3 lung epithelial cells, SARS-CoV-2 sensing mainly occurred through MDA-5. In agreement with previous studies (Felgenhauer et al., 2020; Lokugamage et al., 2020; Mantlo et al., 2020) , we then observed that a 24 h pre-treatment with increasing doses of type I IFN proportionally limited SARS-CoV-2 replication in Vero E6 cells, with the best dose being 1000 U/mL ( Figure S5 ). Interestingly, pre-exposure of HAE and Calu-3 cells with 1000 U/mL IFN potently decreased SARS-CoV-2 RNA amounts in infected cells (by 1,5-2 logs) and the production of infectious viruses (by several orders of magnitude; Figure   4A -B and D-E). Immunofluorescence staining failed to detect dsRNA in SARS-CoV-2 infected cells following IFN pre-treatment in HAE cells, contrary to what was observed in non-treated cells ( Figure 4C ). Intracellular spike staining in infected Calu-3 cells showed a 10-fold decrease in the percentage of infected cells following IFN pre-exposure ( Figure 4F) and immunoblot analysis confirmed a potent inhibition of Nucleocapsid (N) and Spike expression, concomitant with ISG induction ( Figure 4G ). Of note, type I IFN pre-treatment had also a very strong impact on infection in A549-ACE2 cells but a milder effect in Caco-2-ACE2 cells ( Figure S6 ). It was quite striking that the concentrations of type I IFN used here for pre-treatment were similar to what was naturally produced by the infected cells ( Figures 1C, 2A and S3A ), however high levels of replication were observed in the absence of exogenous IFN treatment. We therefore hypothesized that the IFN produced during the course of infection did not have an impact on replication. Indeed, we observed that MDA-5 and MAVS knockout in Calu-3 cells did not impact viral production, despite preventing IFN production ( Figure S7 and Figure 3 ). In order to confirm this, we used CRISPR/Cas9 to disrupt genes belonging to the common signalling pathway for type I and III IFNs, rather than the distinct type I and III IFN receptors. Hence, we generated IRF9 and control (CTRL) KO Calu-3 cell populations and we observed that IRF9 knockout did not substantially improved SARS-CoV-2 replication ( Figure 4H ), whereas the KO cells were not able anymore to induce prototype ISG expression following IFN treatment ( Figure   4I ). Similar data were obtained in JAK1 knockout A549-ACE2 cells and similarly unable to respond to IFN ( Figure S8 ). In line with these results, we observed that contrary to preexposure, IFN exposure 24 h post-infection did not have an impact on SARS-CoV-2 replication efficiency ( Figure S9 ). Moreover, when added as early as 8 h post infection, IFN treatment had an impact only at the lowest MOIs used ( Figure S9 ). 

Here, we characterized host cell responses to SARS-CoV-2 replication in primary, air-liquid HAE cultures and in model cell lines. We confirmed the potent induction of innate responses following infection of HAE cells with SARS-CoV-2 (Pizzorno et al., 2020) , with an important but somewhat late induction of type I and III IFNs. In contrast to our results, a lack of IFN response in HAE cells exposed to SARS-CoV-2 was recently reported (Vanderheiden et al., 2020) . Of note, viral production in the HAE model we used was several magnitudes of order higher than what was reported in the other study (up to 10 7 PFU/mL in washes from the apical side, Figure 4B of this study, in comparison to ~2-3.10 2 PFU/mL, (Vanderheiden et al., 2020) ), which could explain the observed difference in sensing, in addition to inherent differences in the HAE models used. A lack of IFN induction was also reported upon SARS-CoV-2 infection of normal human bronchial epithelial (NHBE) cells (Blanco-Melo et al., 2020) . However, in this study, only 0.1% of total deep sequencing reads were from the virus in this cell type, which was a percentage highly similar to what was observed in wild-type A549 cells (i.e. devoid of Ace2) (Blanco-Melo et al., 2020), known to be refractory to replication because of the lack of ACE2 expression. This strongly suggested poor replication efficiency in this particular model, again explaining the lack of sensing. In support of our data, and in addition to the aforementioned previous report in HAE cells (Pizzorno et al., 2020) , an IFN induction has also been reported in human intestinal organoids (Lamers et al., 2020; Stanifer et al., 2020) . observed. It will be of high interest to further explore the potential regulation of the inflammasome by SARS-CoV-2 and determine whether it is activated and, if that were the case, why there is no IL-1b production by the infected cells.

In agreement with an important role of MDA-5 in host responses to MHV infection in mice (Zalinger et al., 2015) , CRISPR/Cas9 knockout approaches showed that MDA-5 was the main sensor for SARS-CoV-2 in Calu-3 lung epithelial cells, with no impact of RIG-I in this particular model. Whether that would be the case in primary HAE cells remained to be determined, but it has so far proven difficult to genetically modify these cells.

As cells. This suggested that IFNs were produced too late to efficiently prevent replication, as proposed in another study (Lei et al., 2020b) and/or did not efficiently induced ISG expression.

In agreement with this, we observed that knocking-out genes essential for type I and III Zhang et al., 2020) . This highlights the importance to identify the IFN-induced antiviral effectors, which are so potently active against SARS-CoV-2, in order to potentially guide future, targeted therapeutic interventions.

The pRRL.sin.cPPT.SFFV/IRES-puro.WPRE lentiviral vector has been described (Doyle et al., 2018) . Human ACE2 (NM_021804) and TMPRSS2 

Lentiviral vector stocks were obtained by polyethylenimine (PEI; for LentiGuides) or

Lipofectamine 3000 (Thermo Scientific; for ACE2 and TMPRSS2 lentiviral vectors)mediated multiple transfection of 293T cells in 6-well plates with vectors expressing Gag-Pol, the miniviral genome, the Env glycoprotein at a ratio of 1:1:0.5. The culture medium was changed 6 h post-transfection, and vector containing supernatants harvested 36 h later, filtered and used directly or stored at -80°C.

The repeats. Triplicate reactions were run according to the manufacturer's instructions using a ViiA7 Real Time PCR system (ThermoFisher Scientific). For ISG expression, GAPDH and/or ACTB mRNA expression was used to normalize samples. pRdRp (which contains an RdRp fragment amplified from SARS-CoV-2 infected cell RNAs using primers

RdRp_for and RdRp_rev and cloned into pPCR-Blunt II-TOPO) was diluted in 20 ng/ml salmon sperm DNA to generate a standard curve to calculate relative cDNA copy numbers and confirm the assay linearity (detection limit: 10 molecules of RdRp per reaction).

The RT 2 First Strand kit (Qiagen) was used for the synthesis of the complementary DNA strand using 400 µg of total RNA from samples extracted using the RNeasy kit (Qiagen) employing on-column DNase treatment. RT 2 Profiler™ PCR Array Human Antiviral

Response (PAHS-122Z) was used in the present study, according to manufacturer's instructions. The ViiA7 Real Time PCR system (ThermoFisher Scientific) was used to amplify the DNA with a thermal cycling of 95 °C for 10 min followed by 40 cycles of 15 s at 95°C and 60 s at 60°C. Five housekeeping genes (β-actin (ACTB), β-2-microglobulin (B2M), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hypoxanthine phosphoribosyltransferase1 (HPRT1) and ribosomal protein, large, P0 (HPLP0) were used as internal controls. The average of the Ct values from these 5 controls was used to normalize gene expression. Changes in mRNA expression between the non-infected and the infected conditions were analysed using the ΔΔCt method.

The concentration of 13 secreted cytokines was measured in the supernatants and basal media of infected Calu-3 and HAE cells, respectively, at the indicated conditions, using

LEGENDplex bead-based immunoassays (BioLegend, human anti-virus response panel), according to the manufacturer's recommendations. Samples were analysed on a BD Canto II flow cytometer using the Diva software (BD Biosciences, San Jose, CA).

BioLegend's LEGENDplex Data Analysis Software was used to analyse data.

HAE cells were pre-treated or not with IFN for 20 h and infected with SARS-CoV2, as 

HEK-Blue™ IFN-α/β cells and HEK-Blue™ IFN-l (InvivoGen) were plated at 30,000 cells per well in a 96-well plate. The following day, media from infected cells (or control cells) was added and a standard curve was generated in parallel by serial dilutions of type I or type III IFNs in complete DMEM. After 20-24 h incubation, 30 µl of HEK-Blue™ IFN-α/β supernatants was added to 120 uL of Quanti-blue™ substrate (InvivoGen) and incubated at 37°C for 15 min. Absorbance was measured at 620nm using an Envision plate reader (Perkin-Elmer). The standard curves were used to provide semi-quantitative analyses of the IFN concentrations produced by the infected cells. 

The datasets generated during and/or analysed during the current study are available from the corresponding authors on reasonable request.

Requests for material should be addressed to Caroline Goujon or Olivier Moncorgé at the corresponding address above, or to Addgene for the plasmids with an Addgene number.

(to R.P.) and a 2-year post-doctoral grant from the Agence Nationale de la Recherche sur le SIDA et les Hépatites virales, ANRS (to GM). We acknowledge the imaging facility MRI, member of the national infrastructure France-BioImaging supported by the French National

Research Agency (ANR-10-INBS-04) and the CEMIPAI BSL-3 facility.

The authors have no conflicts of interest to declare in relation to this manuscript. AIM2  APOBEC3G  ATG5  AZI2  CARD9  CASP1  CASP10  CASP8  CCL3  CCL5  CD40  CD80  CD86  CHUK  CTSB  CTSL  CTSS  CXCL10  CXCL11  CXCL9  CYLD  TKFC  DDX3X  DDX58  DHX58  FADD  FOS  HSP90AA1  IFIH1  IFNA1  IFNA2  IFNAR1  IFNB1  IKBKB  IL12A  IL12B  IL15  IL18  IL1B  IL6  CXCL8  IRAK1  IRF3  IRF5  IRF7  ISG15  JUN  MAP2K1  MAP2K3  MAP3K1  MAP3K7  MAPK1  MAPK14  MAPK3  MAPK8  MAVS  MEFV  MX1  MYD88  NFKB1  NFKBIA  NLRP3  NOD2  OAS2  PIN1  PSTPIP1  PYCARD  PYDC1  RELA  RIPK1  SPP1  STAT1  SUGT1  TBK1  TICAM1  TLR3  TLR7  TLR8  TLR9  TNF  TRADD  TRAF3  TRAF6  TRIM25 10 -1 Calu-3 knockout cells were infected with SARS-CoV-2 at MOI 0,05 (as in Figure 3 ) and viral production was measured 48 h later by plaque assays on Vero E6 cells. The mean of 2 independent experiments is shown, with error bars representing one s.d. from the mean. 

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans

Auto-antibodies against type I IFNs in patients with life-threatening COVID-19

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Control of coronavirus infection through plasmacytoid dendriticcell-derived type I interferon

Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

An inflammatory cytokine signature predicts COVID-19 severity and survival

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation

The interferoninducible isoform of NCOA7 inhibits endosome-mediated viral entry

Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome

Inhibition of SARS-CoV-2 by type I and type III interferons

Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection

Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

Type III IFNs: Beyond antiviral protection

SARS-CoV-2 productively infects human gut enterocytes

Shared and Distinct Functions of Type I and Type III Interferons

Activation and evasion of type I interferon responses by SARS-CoV-2

Activation and evasion of type I interferon responses by SARS-CoV-2

Murine Coronavirus Induces Type I Interferon in Oligodendrocytes through Recognition by RIG-I and MDA5

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV

Antiviral activities of type I interferons to SARS-CoV-2 infection

Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2

SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling

SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models

Type I and Type III Interferons -Induction, Signaling, Evasion, and Application to Combat COVID-19

Coronavirus as a possible cause of severe acute respiratory syndrome

Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia

Interplay between SARS-CoV-2 and the type I interferon response

Improved vectors and genome-wide libraries for CRISPR screening

High Secretion of Interferons by Human Plasmacytoid Dendritic Cells upon Recognition of Middle East Respiratory Syndrome Coronavirus

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells

Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures

Guarding the frontiers: the biology of type III interferons

MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment

Evasion of Type I Interferon by SARS-CoV-2

Evidence for Gastrointestinal Infection of SARS-CoV-2

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

MDA5 Is Critical to Host Defense during Infection with Murine Coronavirus

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Potent Inhibition of SARS-Associated Coronavirus (SCoV) Infection and Replication by Type I Interferons (IFN-α/β ) but Not by Type II Interferon (IFN-γ )

Epidemiology and cause of severe acute respiratory syndrome

People's Republic of China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A Novel Coronavirus from Patients with Pneumonia in China

We wish to thank Raphaël Gaudin, Laurence Briant, Sylvie Van der Werf, Eric Bernard, Emma Partiot, Aurélie Lieuvin, Hélène Bauby, Mélanie Wencker for the generous provision of reagents, protocols and/or for helpful discussions. We are immensely grateful to Christine Chable-Bessia for setting up excellent working conditions for SARS-CoV-2 handling at the CEMIPAI BSL-3 facility.